Skip to content

EXOZ EXOZ Amortization

Amortization at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Other financials

Income statement

See full
Revenue$17.5K
Operating income-$2.4M-22.4%
Net income-$2.4M-27.7%
EPS (diluted)-$0.28-27.3%

Balance sheet

See full
Cash & equivalents$1.4M-83.0%
Total debt$1.2M-8.8%
Total equity$1.5M-82.8%
Total assets$4.0M-65.1%

Cash flow

See full
Operating cash flow-$1.5M-34.5%
CapEx$57.6K+85.5%
Free cash flow-$1.6M-35.8%

Valuation

See full
Market cap$76.8M-5.6%
Enterprise value$76.57M+1.0%
P/S1,096.1×

Profitability

See full
Operating margin-14,489.6%
Net margin-2,909.1%
FCF margin-10,117.8%

Returns & leverage

See full
Return on equity-185.8%
Debt / equity0.8×+0.6×
Current ratio1.3×-5.2×

Where this comes from

Reported directly by EXOZ in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentForAmortization.

The official record: EXOZ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about EXOZ's amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EXOZ's amortization?
EXOZ (EXOZ) reported amortization of -$11.99K in Q1 2026.
How has EXOZ's amortization changed year-over-year?
EXOZ's amortization increased by 10.9% year-over-year, from -$13.46K to -$11.99K.
What is the long-term trend for EXOZ's amortization?
Over 2 years (2023 to 2025), EXOZ's amortization has grown at a 1.0% compound annual growth rate (CAGR), from -$51.84K to -$52.91K.